蒂作为结直肠癌中潜在的新型治疗点
Hongyun Wei1, Keyu Ren1, Qian Zhang1
1Department of Gastroenterology, Affiliated Hospital of Qingdao University, Qingdao, China.
Journal of cellular and molecular medicine
|July 27, 2023
概括
在结肠直肠癌 (CRC) 中,滴度 (TTN) 降低,与晚期和较差的存活率相关. 这项研究探讨了TTN作为CRC的潜在治疗点,为治疗提供了新的途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 大肠直肠癌 (CRC) 是全球主要的死亡原因.
- 目前用于CRC的化疗方法往往不具有成本效益,需要新的治疗点.
- 肌肉蛋白Titin (TTN) 在CRC致癌中的作用尚不清楚.
研究的目的:
- 调查蒂 (TTN) 在结直肠癌 (CRC) 发展和进展中的潜在作用.
- 分析CRC组织和细胞系中的TTN表达水平.
- 探索TTN表达与临床参数,患者存活率和潜在的治疗反应之间的相关性.
主要方法:
- 在癌症基因组图谱 (TCGA) 数据库中对CRC组织与正常对照对TTNmRNA和蛋白质表达的分析.
- 对TTN表达与临床阶段,转移,组织学类型,种族和TP53突变状态的相关性分析.
- 在CRC细胞系中评估TTN表达和评估TTN过度表达对细胞增殖,转移和侵入的影响.
- 基因组丰富分析 (GSEA) 以确定相关途径和TTN参与对阿扎丁的反应.
主要成果:
- 与正常组织相比,CRC组织中的TTN表达显著下调 (p < 0.05).
- 较低的TTN表达与晚期临床阶段,淋巴结转移,腺癌组织学,特定种族群体和TP53突变相关 (p <0.05).
- 更高的TTN表达与显著更短的整体存活率有关.
- 在CRC细胞系中,TTN的表达低,其过度表达促进了增殖,转移和入侵.
- 该ERB途径与TTN相关的CRC有关,TTN参与了对阿扎丁的反应.
结论:
- 泰 (TTN) 在结直肠癌 (CRC) 中表现出显著的下调,并与不良临床结果相关.
- 在CRC中,TTN可能起到瘤抑制作用,其下调促进癌症的进展.
- TTN代表了一种潜在的新型治疗点,用于治疗CRC和克服化疗耐药性.
更多相关视频
08:47Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
115
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
6.0K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
